Literature DB >> 6194309

Identification of four complementary RNA species in Akabane virus-infected cells.

A K Pattnaik, G Abraham.   

Abstract

The analysis of RNA extracted from purified Akabane virus demonstrated the presence of three size classes of single-stranded RNAs with sedimentation coefficients of 31S (large, L), 26S (medium, M), and 13S (small, S). Molecular weights of these RNA species were estimated to be 2.15 X 10(6), 1.5 X 10(6), and 0.48 X 10(6) for the L, M, and S RNAs, respectively. Hybridization analysis involving viral genomic RNA and RNA from virus-infected cells resulted in the identification of four virus-specific cRNA species in infected cells. These cRNAs were found to be nonpolyadenylated by their inability to bind to oligodeoxythymidylate-cellulose. Kinetic analysis of cRNA synthesis in infected cells at various times postinfection suggested that cRNA synthesis could be detected as early as 2 h postinfection and that maximal synthesis occurred at 4 to 6 h postinfection. The RNAs synthesized in infected cells could be partially resolved by sucrose density gradient centrifugation. The RNA fraction that cosedimented with the S segment of viral genomic RNA yielded two duplex RNA species when hybridized with viral genomic RNA, suggesting the presence of two small cRNA species. Specific hybridization with individual viral genomic RNAs confirmed that two species of cRNA are coded by the S RNA segment. Analysis of cRNA synthesis in the presence of the protein synthesis inhibitors cycloheximide and puromycin indicated that cycloheximide completely inhibited virus-specific RNA synthesis early and late in infection, whereas a very low level of synthesis occurred in the presence of puromycin. The inhibitory effects of these drugs were found to be reversible when the drugs were washed from the cells. It is concluded that continued protein synthesis is required for cRNA synthesis to proceed in Akabane virus-infected cells.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6194309      PMCID: PMC255286     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

1.  Quantitative film detection of 3H and 14C in polyacrylamide gels by fluorography.

Authors:  R A Laskey; A D Mills
Journal:  Eur J Biochem       Date:  1975-08-15

2.  Bunyamwera virus. I. The molecular complexity of the virion RNA.

Authors:  R J Kascsak; M J Lyons
Journal:  Virology       Date:  1977-10-01       Impact factor: 3.616

3.  Transcription of the influenza virus genome.

Authors:  A J Hay; B Lomniczi; A R Bellamy; J J Skehel
Journal:  Virology       Date:  1977-12       Impact factor: 3.616

4.  Sendai virus RNA synthesis and nucleocapsid formation in the presence of cycloheximide.

Authors:  W S Robinson
Journal:  Virology       Date:  1971-06       Impact factor: 3.616

5.  Primary transcription of the influenza virus genome in permissive cells.

Authors:  W J Bean; R W Simpson
Journal:  Virology       Date:  1973-12       Impact factor: 3.616

6.  A film detection method for tritium-labelled proteins and nucleic acids in polyacrylamide gels.

Authors:  W M Bonner; R A Laskey
Journal:  Eur J Biochem       Date:  1974-07-01

7.  Synthesis in vivo of influenza virus plus and minus strand RNA and its preferential inhibition by antibiotics.

Authors:  C Scholtissek; R Rott
Journal:  Virology       Date:  1970-04       Impact factor: 3.616

8.  Structural proteins of La Crosse virus.

Authors:  J F Obijeski; D H Bishop; F A Murphy; E L Palmer
Journal:  J Virol       Date:  1976-09       Impact factor: 5.103

9.  Interferon action: inhibition of vesicular stomatitis virus RNA synthesis induced by virion-bound polymerase.

Authors:  P I Marcus; D L Engelhardt; J M Hunt; M J Sekellick
Journal:  Science       Date:  1971-11-05       Impact factor: 47.728

10.  Small viral RNA segment of bunyaviruses codes for viral nucleocapsid protein.

Authors:  J R Gentsch; D H Bishop
Journal:  J Virol       Date:  1978-10       Impact factor: 5.103

View more
  19 in total

1.  Bunyavirus mRNA synthesis is coupled to translation to prevent premature transcription termination.

Authors:  John N Barr
Journal:  RNA       Date:  2007-03-30       Impact factor: 4.942

2.  Germiston virus transcriptase requires active 40S ribosomal subunits and utilizes capped cellular RNAs.

Authors:  P Vialat; M Bouloy
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

3.  The translational requirement for complete La Crosse virus mRNA synthesis is cell-type dependent.

Authors:  R Raju; L Raju; D Kolakofsky
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

4.  Rift Valley fever virus M segment: use of recombinant vaccinia viruses to study Phlebovirus gene expression.

Authors:  L T Kakach; T L Wasmoen; M S Collett
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

5.  Translational requirement of La Crosse virus S-mRNA synthesis: in vivo studies.

Authors:  R Raju; D Kolakofsky
Journal:  J Virol       Date:  1987-01       Impact factor: 5.103

6.  Translational requirement of La Crosse virus S-mRNA synthesis: in vitro studies.

Authors:  C Bellocq; R Raju; J Patterson; D Kolakofsky
Journal:  J Virol       Date:  1987-01       Impact factor: 5.103

7.  Translational requirement for La Crosse virus S-mRNA synthesis: a possible mechanism.

Authors:  C Bellocq; D Kolakofsky
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

8.  Characterization of La Crosse virus small-genome transcripts.

Authors:  J L Patterson; D Kolakofsky
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

9.  A transcript from the S segment of the Germiston bunyavirus is uncapped and codes for the nucleoprotein and a nonstructural protein.

Authors:  M Bouloy; P Vialat; M Girard; N Pardigon
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

10.  Nuclear relocalization of polyadenylate binding protein during rift valley fever virus infection involves expression of the NSs gene.

Authors:  Anna Maria Copeland; Louis A Altamura; Nicole M Van Deusen; Connie S Schmaljohn
Journal:  J Virol       Date:  2013-08-21       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.